[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-resp-tract-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-resp-tract-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100583472","effect-of-pediatric-lung-ultrasound-on-antibiotic-prescriptions-in-hospitalized-children-and-adolescents-with-lower-respiratory-tract-infections-a-randomized-controlled-trial-100583472",false,"NCT06876766","Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents With Lower Respiratory Tract Infections. A Randomized Controlled Trial.","Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents With Lower Respiratory Tract Infections.","PLUS-AP","Inclusion Criteria:\n\n* Age between 3 months and 17 years old inclusive\n* Currently admitted to the pediatric Ward or boarding in the Emergency Department within 24 hours of admission order due to lower respiratory tract infections.\n\nExclusion Criteria:\n\n* Sickle cell disease (SCD).\n* On chemotherapy or any other immunosuppressive therapy except systemic corticosteroids use of ≤ 5 days duration.\n* Cystic fibrosis and other chronic lung diseases except asthma\n* Pre-existing and\u002For congenital neurologic, metabolic, and cardiac conditions\n* Hospitalized within the previous month\n* Patients with suspected foreign body aspiration -Received antibiotic therapy within the previous week\n* Patients admitted under PI's care","ALL","3 Months","18 Years",{"count":21,"type":22},176,"ESTIMATED","INTERVENTIONAL",[25],"NA","Title: Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents with Lower Respiratory Tract Infections (PLUS-AP Trial)\n\nPurpose of the Study:\n\nThis study is being done to find out if a type of imaging called lung ultrasound (LUS) can help doctors decide when to stop antibiotics in children and teens who are in the hospital with lung infections, like pneumonia. Antibiotics are often given to these patients, but sometimes they are used for longer than necessary, which can be harmful. The investigators want to see if using LUS helps doctors make decisions that reduce unnecessary antibiotic use, which can help prevent antibiotic resistance and other complications.\n\nWhat is Lung Ultrasound (LUS)? Lung ultrasound is a safe, non-invasive, and painless test that uses sound waves to look at the lungs. It doesn't involve radiation like chest X-rays. It is already being used to help doctors understand lung conditions, and this study will test if it can also help in deciding when to stop antibiotics.\n\nHow the Study Works:\n\nParticipants: Children and adolescents (ages 3 months-18 years) who are admitted to the hospital with a lung infection.\n\nGroups:\n\nLUS Group: These patients will have a lung ultrasound within 24 hours of enrollment. The results will help guide decisions about when to stop antibiotics.\n\nStandard Care Group: These patients will receive regular hospital care, which may include chest X-rays and other tests to guide their treatment.\n\nWhat Will Be Measured?\n\nPrimary Goal: The study will measure how long children and teens stay on antibiotics. The investigators are testing whether LUS can help shorten this time without affecting their recovery.\n\nSecondary Goals: Investigators will also look at how long patients stay in the hospital, whether they need further treatment or care after leaving.\n\nWhy is This Important? If this study shows that LUS can safely reduce the use of antibiotics, it could change how doctors treat lung infections in children. Reducing unnecessary antibiotic use can help fight antibiotic resistance and protect children from side effects of unnecessary treatments.",[28],"Lower Resp Tract Infection","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-04-02",{"date":37,"type":22},"2027-06",{"name":39,"class":40},"American University of Beirut Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100642705","holistic-approach-supporting-the-uptake-of-innovative-diagnostic-technologies-for-respiratory-infections-100642705","NCT07651865","Holistic Approach Supporting the Uptake of Innovative Diagnostic Technologies for Respiratory Infections","Clinical Validation of Novel Microfluidic and Lateral Flow-based Technologies for the Detection of Lower and Upper Respiratory Tract Infections - HOLICARE Trial","HOLICARE","Inclusion Criteria:\n\n* Age ≥ 6 months\n* Presentation with suspected respiratory tract infection and at least two of the following symptoms:\n* Fever (axillary temperature ≥37.5°C) or history of fever\n* New acute cough episode\n* Shortness of breath\n* Tachypnoea (fast breathing)\n* Loss of smell and\u002For taste\n* Ability to provide written informed consent (or assent with parent\u002Fguardian consent for minors)\n* For infants (≤1 year), both fever and new acute cough must be present at screening\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\u002Fassent\n* Refusal to provide study samples\n* Severe chronic medical conditions or mental incapacity that, in the opinion of the clinician, would interfere with study participation\n* Hospitalisation within the previous 2 weeks for reasons unrelated to the current respiratory symptoms\n* Acute injury, trauma, or poisoning interfering with participation\n* Chronic cough lasting \\>2 weeks, unless tuberculosis is suspected in the LRTI cohort\n* Antibiotic use within the previous 2 weeks for participants enrolled in the LRTI cohort (Sub-study 2) only","6 Months",{"count":52,"type":22},2160,"OBSERVATIONAL","This observational diagnostic validation study aims to evaluate the clinical performance of novel lateral flow and microfluidic-based technologies for the detection of upper and lower respiratory tract infections in children and adults presenting with respiratory symptoms in Uganda, Ethiopia, and Senegal. The main questions it aims to answer are:\n\n1. whether the novel multiplex lateral flow tests and point-of-care microfluidic platform demonstrate sufficient sensitivity and specificity for detecting respiratory pathogens compared with standard laboratory reference methods, and\n2. whether these technologies are feasible and usable in low-resource clinical settings.\n\nParticipants presenting with suspected respiratory tract infections as part of routine clinical care will provide respiratory and blood samples for diagnostic testing and biobanking, and demographic and clinical information will be collected during a single study visit. Some adult participants and community stakeholders will also complete surveys or interviews regarding the acceptability of biobanking and diagnostic implementation.",[56,28],"Upper Respiratory Infection",[58,59,60,61,62,63],"Point of Care","POC","Later Flow Test (LFT)","Global Health","Rapid diagnostic","Microfluidics","2026-06-24",{"date":66,"type":33},"2026-06-29",{"date":68,"type":33},"2025-04-07",{"date":70,"type":22},"2026-08-31",{"name":72,"class":40},"Karolinska Institutet",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100541553","treatment-of-lower-respiratory-tract-infection-in-selected-hospitals-in-southern-sri-lanka-treat-sl-a-stepped-wedge-cluster-randomized-trial-100541553","NCT06331364","TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge Cluster Randomized Trial","TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): A Stepped-wedge Cluster Randomized Trial of an Electronic Clinical Decision Support Tool (eCDST) for the Diagnosis and Treatment of Lower Respiratory Tract Infection (LRTI) in Selected Hospitals in Southern Sri Lanka","TREAT-SL","Inclusion Criteria:\n\n1. Admitted within prior 48 hours\n2. Have evidence of new acute respiratory illness (\\\u003C14 days of symptoms), as indicated by at least one of the following:\n\n   1. New cough or sputum production\n   2. Chest pain\n   3. Dyspnea or tachypnea (respiratory rate \\>20 breaths\u002Fminute)\n   4. Abnormal lung examination\n3. Have evidence of acute infection, as indicated by at least one of the following:\n\n   1. Self-reported fever or chills\n   2. Documented fever ≥38 ̊ C (100.4 ̊ F)\n   3. Documented hypothermia \\\u003C35.5 ̊ C (95.9 ̊ F)\n   4. Leukocytosis (white blood cell count \\>10,000\u002Fmm3)\n   5. Leukopenia (white blood cell count \\\u003C3000\u002Fmm3)\n   6. New altered mental status\n4. Ability and willingness of patient, parent or legally authorized representative (LAR) to give informed consent\n5. Ability of children 14-17 years of age to provide assent\n6. Ability to complete follow-up encounter at 30 days in person or by telephone\n\nExclusion Criteria:\n\n1. Hospitalized recently (within last 28 days)\n2. If they have been enrolled into this clinical trial previously\n3. Surgery in the past 7 days\n4. If they are unable or unwilling to complete the follow-up encounter\n5. If they will likely be transferred from the medical wards within 24 hours of enrollment (to another ward or to another hospital)\n6. If they have underlying conditions or circumstances for which physicians would be unlikely to withhold antibacterials:\n\n   1. Vasopressor therapy\n   2. Cystic fibrosis\n   3. Known severe immunosuppression (i. Cancer or another condition with neutropenia (absolute neutrophil count \\\u003C1000\u002F microL; ii. Solid- organ or hematopoietic stem-cell transplant within the previous 90 days; iii. Active graft-versus-host disease or bronchiolitis obliterans; iv. On chronic steroids equivalent to prednisone 20mg daily for ≥ 2 weeks or other targeted cytotoxic or biologic immunosuppressants within the prior 4 weeks; v. Human immunodeficiency virus infection with a CD4 cell count \\\u003C200\u002Fmm3)\n   4. Have an accompanying non-respiratory infection\n   5. Have evidence of a lung abscess or empyema\n   6. Have respiratory failure at enrollment, evidenced by use of non-invasive or invasive ventilation","14 Years",{"count":83,"type":22},765,[25],"This is a stepped-wedge, cluster-randomized, two-arm, open-label, clinical trial of an electronic clinical decision support tool (eCDST) for the diagnosis and treatment of lower respiratory tract infection (LRTI) among patients at three sites in Southern Province, Sri Lanka.\n\nThe primary objective of this trial is to determine the impact of an electronic clinical decision support tool (eCDST) on clinical outcomes and antibacterial prescription in subjects with LRTI in the intervention group compared to the control group.\n\nThe study will enroll 765 patients ≥ 14 years of age. Medical wards will be randomized in clusters to the intervention at intervals of 3-6 months until all clusters cross over. Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials prescribed (a maximum of 14 days).",[28],[88],"eCDST","2026-03-12",{"date":91,"type":33},"2026-03-16",{"date":93,"type":33},"2026-02-27",{"date":95,"type":22},"2028-02",{"name":97,"class":40},"Duke University"]